Eight Years of Entecavir Therapy Leads to Cirrhosis Regression—What Does This Mean?

Eight years of entecavir therapy leading to reversal of cirrhosis represents a clinically meaningful milestone in the management of chronic hepatitis B virus (HBV) infection. Entecavir is a potent nucleoside analog reverse transcriptase inhibitor with high barrier to resistance, widely used as first-line antiviral therapy for patients with chronic HBV.

Long-term viral suppression—achieved consistently with entecavir—reduces ongoing hepatocyte injury and inflammation, thereby halting fibrogenesis and enabling hepatic architectural remodeling. Histologic studies, including serial liver biopsies and noninvasive elastography (e.g., transient elastography or MR elastography), have demonstrated regression of bridging fibrosis and even established cirrhosis in a subset of patients after sustained virologic control over 5–10 years.

This phenomenon underscores two critical principles: first, that cirrhosis—particularly early-stage or compensated cirrhosis—is not always an irreversible endpoint; second, that durable HBV DNA suppression is the cornerstone of disease modification in chronic hepatitis B. Importantly, reversal does not equate to complete normalization of liver architecture or elimination of long-term risks: patients who achieve cirrhosis regression remain at elevated risk for hepatocellular carcinoma and require lifelong surveillance with abdominal ultrasound and serum alpha-fetoprotein every six months.

Clinical decision-making must therefore balance optimism about structural improvement with vigilance for residual oncogenic risk. Continued adherence to antiviral therapy, regular monitoring of liver function, HBV DNA levels, and imaging, and avoidance of cofactors such as alcohol or metabolic stressors remain essential components of comprehensive care.